

**Supplementary Table 1:** Eligibility Criteria for participation in Sisonke 2 study.

Inclusion Criteria	Exclusion Criteria	Recommendation for consultation with health care provider and/or Sisonke safety desk	Recommendation for consultation with PSRT
Age 18 and older	Participants who have received boosting vaccination through other means	History of severe adverse reaction associated with a vaccine and/or severe	Chronic history of severe clotting disorders
All Sisonke participants	Participants with a history of heparin-induced thrombocytopenia or TTS	allergic reaction (e.g., anaphylaxis) to any component of the vaccine.	Participants who suffered a thromboembolic adverse event following the
Received a priming Ad26.SARS.COVID.2.S vaccination as part of the Sisonke study at least 6 months prior	Any significant acute or chronic medical condition, situation or circumstance that in the opinion of the PI/designee makes the participant unsuitable for participation in the study or jeopardises the safety or rights of the participant.	Participants who are thought to have suffered a neurological adverse event considered related to the priming Janssen Covid-19 vaccine.	priming Janssen Covid-19 vaccine.
Participants who are pregnant or report breastfeeding at the time of enrolment may be included.			
Willingness and ability to comply with vaccination plan and other study procedures.	Current participation in any other research studies that would interfere with the	Participants reporting a non-infective SAE within the first 28 days following the priming	

Capable of giving electronic or personal signed informed consent	objectives of this study. The determination of whether participation in another study would be exclusionary for a given participant will be made by the PI/designee.	dose of Janssen Covid-19 vaccine in the Sisonke 3B trial.	
--	---	---	--